Víctor Rodríguez-Freixinós

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

Pablo Martínez, Javier Hernández‐Losa, S. Cedrés et al. · PLoS ONE · 2013 · 70 citations · Full text

Medicine, Oncology, Pathology +16

Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)

S. Cedrés, M. A. Montero, Pablo Martínez et al. · Lung Cancer · 2012 · 69 citations

Medicine, Oncology, Pathology +17

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer

Isidre Felip, Cristian P. Moiola, Cristina Megino‐Luque et al. · Gynecologic Oncology · 2019 · 39 citations

Life Sciences, Cell Biology, Oncology +16

Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.

Ignacio Matos, Juan Martín-Liberal, Cinta Hierro et al. · Journal of Clinical Oncology · 2018 · 37 citations

Medicine, Oncology, Cancer Immunology +16

Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

David Chan, Víctor Rodríguez-Freixinós, Mark Doherty et al. · European Journal of Cancer · 2022 · 34 citations

Medicine, Oncology, Metastasis +14